Sex hormone progesterone may save lives after brain injury (The Guardian, 19 February 2010)
The Times Cheltenham Science Festival 2010 needs volunteers

MHRA safety update on Rosiglitazone (Avandia, Avandamet) in the treatment of type 2 diabetes

04 Mar 2010

Following a Europe-wide review of the cardiovascular safety of Rosiglitazone (Avandia, Avandamet), the MHRA have updated the drug's safety profile when used on its own or in combination with insulin, finding that the balance of risks and benefits of rosiglitazone remain favourable in its licensed indications. Further information can be found by following the link below.

MHRA Rosiglitazone profile

Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story

Top stories

Call for nominations for Awards Committee Chair
30 Oct 2024

James M Tanner Award - 2025 nominations open
30 Oct 2024

Would you like to host the BSPED annual meeting?
21 Oct 2024

Most read